Commonwealth Bank of Australia grew its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 275.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 20,899 shares of the medical research company’s stock after purchasing an additional 15,334 shares during the period. Commonwealth Bank of Australia’s holdings in Agilent Technologies were worth $1,237,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in the company. Parallel Advisors LLC raised its holdings in Agilent Technologies by 5.3% in the 2nd quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock worth $157,000 after acquiring an additional 131 shares during the last quarter. Trust Co. of Vermont raised its holdings in Agilent Technologies by 1.8% in the 2nd quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock worth $166,000 after acquiring an additional 50 shares during the last quarter. Penserra Capital Management LLC raised its holdings in Agilent Technologies by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 3,496 shares of the medical research company’s stock worth $184,000 after acquiring an additional 304 shares during the last quarter. Fiduciary Trust Co. purchased a new position in Agilent Technologies in the 2nd quarter worth approximately $186,000. Finally, Genovese Burford & Brothers Wealth & Retirement Plan Management LLC raised its holdings in Agilent Technologies by 17.2% in the 2nd quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 3,319 shares of the medical research company’s stock worth $196,000 after acquiring an additional 486 shares during the last quarter.
A has been the subject of a number of recent analyst reports. BidaskClub lowered shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Barclays PLC restated a “buy” rating and issued a $67.00 price objective on shares of Agilent Technologies in a report on Wednesday, July 19th. Deutsche Bank AG restated a “buy” rating and issued a $66.00 price objective on shares of Agilent Technologies in a report on Thursday, June 22nd. BTIG Research boosted their price objective on shares of Agilent Technologies from $57.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, May 24th. Finally, Jefferies Group LLC boosted their price objective on shares of Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, May 23rd. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $63.91.
In related news, insider Patrick Kaltenbach sold 5,000 shares of the firm’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $61.26, for a total transaction of $306,300.00. Following the completion of the transaction, the insider now owns 45,138 shares of the company’s stock, valued at $2,765,153.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Boon Hwee Koh sold 4,500 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $63.63, for a total transaction of $286,335.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 138,673 shares of company stock valued at $8,690,987.
Shares of Agilent Technologies, Inc. (A) opened at 65.67 on Friday. The company has a market cap of $21.13 billion, a P/E ratio of 33.87 and a beta of 1.30. Agilent Technologies, Inc. has a 12 month low of $42.92 and a 12 month high of $66.42. The stock’s 50 day moving average is $62.22 and its 200-day moving average is $57.91.
Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company posted $0.49 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. On average, equities analysts forecast that Agilent Technologies, Inc. will post $2.32 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/15/commonwealth-bank-of-australia-acquires-15334-shares-of-agilent-technologies-inc-a.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.